The role of macrophages in influenza A virus infection

Future Virology

Volumn 9, Issue 9, 2014, Pages 847-862

  Nicol, Marlynne Q ^a   Dutia, Bernadette M ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

alveolar macrophage; infection; influenza A virus; lung; macrophage

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RANTES; TUMOR NECROSIS FACTOR ALPHA;

AUTOFLUORESCENCE; CELL INTERACTION; CELL POPULATION; CYTOKINE PRODUCTION; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A; INFLUENZA VIRUS; LUNG ALVEOLUS EPITHELIUM; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PATHOGENESIS; PATHOGENICITY; PNEUMONIA; REVIEW; STEADY STATE; VIRUS STRAIN;

EID: 84908248922     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.14.65     Document Type: Review

References (146)

1. Infuenza (Seasonal) Fact sheet Number 211 (March 2014). http://who.int/mediacentre/factsheets/fs211/en
2. Thompson W W, Shay DK, Weintraub E et al. Mortality associated with infuenza and respiratory syncytial virus in the United States. JAMA 289(2), 179-186 (2003).
3. Thompson W W, Shay DK, Weintraub E et al. Infuenza-associated hospitalizations in the United States. JAMA 292(11), 1333-1340 (2004).
4. Zhou H, Thompson W W, Viboud CG et al. Hospitalizations associated with infuenza and respiratory syncytial virus in the United States, 1993-2008. Clin. Infect. Dis. 54(10), 1427-1436 (2012).
5. Peiris JS, Cheung CY, Leung CY, Nicholls JM. Innate immune responses to infuenza A H5N1: friend or foe? Trends Immunol. 30(12), 574-584 (2009).
6. Tumpey TM, Garcia-Sastre A, Taubenberger JK et al. Pathogenicity of infuenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J. Virol. 79(23), 14933-14944 (2005).
7. Szretter KJ, Gangappa S, Lu X et al. Role of host cytokine responses in the pathogenesis of avian H5N1 infuenza viruses in mice. J. Virol. 81(6), 2736-2744 (2007).
8. Beigel JH, Farrar J, Han AM et al. Avian infuenza A (H5N1) infection in humans. N. Engl. J. Med. 353(13), 1374-1385 (2005).
9. Askovich PS, Sanders CJ, Rosenberger CM et al. Differential host response, rather than early viral replication effciency, correlates with pathogenicity caused by infuenza viruses. PLoS ONE 8(9), e74863 (2013).
10. Bender BS, Small PA Jr. Infuenza: pathogenesis and host defense. Semin. Respir. Infect. 7(1), 38-45 (1992).
11. Rodgers BC, Mims CA. Infuenza virus replication in human alveolar macrophages. J. Med. Virol. 9(3), 177-184 (1982).
12. Gordon SB, Read RC. Macrophage defences against respiratory tract infections. Br. Med. Bull. 61, 45-61 (2002).
13. Janssen WJ, Barthel L, Muldrow A et al. Fas determines differential fates of resident and recruited macrophages during resolution of acute lung injury. Am. J. Respir. Crit. Care Med. 184(5), 547-560 (2011).
14. Maus UA, Janzen S, Wall G et al. Resident alveolar macrophages are replaced by recruited monocytes in response to endotoxin-induced lung infammation. Am. J. Respir. Cell Mol. Biol. 35(2), 227-235 (2006).
15. Crapo JD, Harmsen AG, Sherman MP, Musson RA. Pulmonary immunobiology and infammation in pulmonary diseases. Am. J. Respir. Crit. Care Med. 162(5), 1983-1986 (2000).
16. Yona S, Kim KW, Wolf Y et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 38(1), 79-91 (2013).
17. Landsman L, Jung S. Lung macrophages serve as obligatory intermediate between blood monocytes and alveolar macrophages. J. Immunol. 179(6), 3488-3494 (2007).
18. Hashimoto D, Chow A, Noizat C et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 38(4), 792-804 (2013).
19. Davies LC, Jenkins SJ, Allen JE, Taylor PR. Tissue-resident macrophages. Nat. Immunol. 14(10), 986-995 (2013).
20. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 3(1), 23-35 (2003).
21. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 6, 13 (2014).
22. Spence S, Fitzsimons A, Boyd CR et al. Suppressors of cytokine signaling 2 and 3 diametrically control macrophage polarization. Immunity 38(1), 66-78 (2013).
23. Pauli EK, Schmolke M, Wolff T et al Infuenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression. PLoS Pathog. 4(11), e1000196 (2008).
24. Pothlichet J, Chignard M, Si-Tahar M. Cutting edge: innate immune response triggered by infuenza A virus is negatively regulated by SOCS1 and SOCS3 through a RIG-I/IFNAR1-dependent pathway. J. Immunol. 180(4), 2034-2038 (2008).
25. Wang J, Nikrad MP, Travanty EA et al. Innate immune response of human alveolar macrophages during infuenza A infection. PLoS ONE 7(3), e29879 (2012).
26. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S. Macrophage receptors and immune recognition. Annu. Rev. Immunol. 23, 901-944 (2005).
27. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5(12), 953-964 (2005).
28. Pluddemann A, Mukhopadhyay S, Gordon S. Innate Immunity to intracellular pathogens: macrophage receptors and responses to microbial entry. Immunol. Rev. 240(1), 11-24 (2011).
29. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 32(5), 593-604 (2010).
30. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27, 451-483 (2009).
31. Xu W, Roos A, Schlagwein N, Woltman AM, Daha MR, Van Kooten C. IL-10-producing macrophages preferentially clear early apoptotic cells. Blood 107(12), 4930-4937 (2006).
32. Verreck FA, De Boer T, Langenberg DM, Van Der Zanden L, Ottenhoff TH. Phenotypic and functional profling of human proinfammatory type-1 and anti-infammatory type-2 macrophages in response to microbial antigens and IFN-gamma-and CD40L-mediated costimulation. J. Leukoc. Biol. 79(2), 285-293 (2006).
33. Toews GB, Vial WC, Dunn MM et al. The accessory cell function of human alveolar macrophages in specifc T cell proliferation. J. Immunol. 132(1), 181-186 (1984).
34. Shaykhiev R, Krause A, Salit J et al. Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J. Immunol. 183 (4), 2867-2883 (2009).
35. Melgert BN, Oriss TB, Qi Z et al. Macrophages: regulators of sex differences in asthma? Am. J. Respir. Cell Mol. Biol. 42(5), 595-603 (2010).
36. Pechkovsky DV, Prasse A, Kollert F et al. Alternatively activated alveolar macrophages in pulmonary fbrosis-mediator production and intracellular signal transduction. Clin. Immunol. 137(1), 89-101 (2010).
37. Misharin AV, Morales-Nebreda L, Mutlu GM, Budinger GR, Perlman H. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. Am. J. Respir. Cell Mol. Biol. 49(4), 503-510 (2013).
38. Liu G, Ma H, Qiu L et al. Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+ T cells in mice. Immunol. Cell Biol. 89(1), 130-142 (2011).
39. Tomlinson GS, Booth H, Petit SJ et al. Adherent human alveolar macrophages exhibit a transient pro-infammatory profle that confounds responses to innate immune stimulation. PLoS ONE 7(6), e40348 (2012).
40. Lacey DC, Achuthan A, Fleetwood AJ et al. Defning GM-CSF-and macrophage-CSF-dependent macrophage responses by in vitro models. J. Immunol. 188(11), 5752-5765 (2012).
41. Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whitsett JA, Trapnell BC. GM-CSF regulates alveolar macrophage differentiation and innate Immunity in the lung through PU.1. Immunity 15(4), 557-567 (2001).
42. Trapnell BC, Whitsett JA. GM-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. Annu. Rev. Physiol. 64, 775-802 (2002).
43. Huang H, Li H, Zhou P, Ju D. Protective effects of recombinant human granulocyte macrophage colony stimulating factor on H1N1 infuenza virus-induced pneumonia in mice. Cytokine 51(2), 151-157 (2010).
44. Huang FF, Barnes PF, Feng Y et al. GM-CSF in the lung protects against lethal infuenza infection. Am. J. Respir. Crit. Care Med. 184(2), 259-268 (2011).
45. Duan M, Li WC, Vlahos R, Maxwell MJ, Anderson GP, Hibbs ML. Distinct macrophage subpopulations characterize acute infection and chronic infammatory lung disease. J. Immunol. 189(2), 946-955 (2012).
46. Boldrick JC, Alizadeh AA, Diehn M et al. Stereotyped and specifc gene expression programs in human innate immune responses to bacteria. Proc. Natl Acad. Sci. USA 99(2), 972-977 (2002).
47. Zaynagetdinov R, Sherrill TP, Kendall PL et al. Identifcation of myeloid cell subsets in murine lungs using fow cytometry. Am. J. Respir. Cell Mol. Biol. 49(2), 180-189 (2013).
48. Garn H. Specifc aspects of fow cytometric analysis of cells from the lung. Exp. Toxicol. Pathol. 57(Suppl. 2), 21-24 (2006).
49. Havenith CE, Breedijk AJ, Van Miert PP et al. Separation of alveolar macrophages and dendritic cells via autofuorescence: phenotypical and functional characterization. J. Leukoc. Biol. 53(5), 504-510 (1993).
50. Landsman L, Varol C, Jung S. Distinct differentiation potential of blood monocyte subsets in the lung. J. Immunol. 178 (4), 2000-2007 (2007).
51. Laskin DL, Weinberger B, Laskin JD. Functional heterogeneity in liver and lung macrophages. J. Leukoc. Biol. 70(2), 163-170 (2001).
52. Edelson JD, MacFadden DK, Klein M, Rebuck AS. Autofuorescence of alveolar macrophages: problems and potential solutions. Med. Hypotheses 17(4), 403-407 (1985).
53. Weyde J, Wassermann K, Schell-Frederick E. Analysis of single and double-stained alveolar macrophages by fow cytometry. J. Immunol. Methods 207(2), 115-123 (1997).
54. Ghoneim HE, Thomas PG, Mccullers JA. Depletion of alveolar macrophages during infuenza infection facilitates bacterial superinfections. J. Immunol. 191(3), 1250-1259 (2013).
55. Sanderson SD, Thoman ML, Kis K et al. Innate immune induction and infuenza protection elicited by a response-selective agonist of human C5a. PLoS ONE 7(7), e40303 (2012).
56. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu. Rev. Immunol. 27, 669-692 (2009).
57. Kaku Y, Imaoka H, Morimatsu Y et al. Overexpression of CD163, CD204 and CD206 on alveolar macrophages in the lungs of patients with severe chronic obstructive pulmonary disease. PLoS ONE 9(1), e87400 (2014).
58. Hogger P, Dreier J, Droste A, Buck F, Sorg C. Identifcation of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cysteine-rich family (CD163). J. Immunol. 161(4), 1883-1890 (1998).
59. Goerdt S, Orfanos CE. Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 10(2), 137-142 (1999).
60. Cao H, Crocker PR. Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation? Immunology 132(1), 18-26 (2010).
61. Feng YH, Mao H. Expression and preliminary functional analysis of Siglec-F on mouse macrophages. J. Zhejiang Univ. Sci. B. 13 (5), 386-394 (2012).
62. Hogner K, Wolff T, Pleschka S et al. Macrophage-expressed IFN-beta contributes to apoptotic alveolar epithelial cell injury in severe infuenza virus pneumonia. PLoS Pathog. 9(2), e1003188 (2013).
63. Fleming TJ, Fleming ML, Malek TR. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J. Immunol. 151(5), 2399-2408 (1993).
64. Nagendra S, Schlueter AJ. Absence of cross-reactivity between murine Ly-6C and Ly-6G. Cytometry A 58(2), 195-200 (2004).
65. Snelgrove RJ, Goulding J, Didierlaurent AM et al. A critical function for CD200 in lung immune homeostasis and the severity of infuenza infection. Nat. Immunol. 9(9), 1074-1083 (2008).
66. Koning N, Van Eijk M, Pouwels W et al. Expression of the inhibitory CD200 receptor is associated with alternative macrophage activation. J. Innate Immun. 2(2), 195-200 (2010).
67. Guth AM, Janssen WJ, Bosio CM, Crouch EC, Henson PM, Dow SW. Lung environment determines unique phenotype of alveolar macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 296(6), L936-L946 (2009).
68. Ducreux J, Crocker PR, Vanbever R. Analysis of sialoadhesin expression on mouse alveolar macrophages. Immunol. Lett. 124(2), 77-80 (2009).
69. Xiong YS, Cheng Y, Lin QS et al. Increased expression of Siglec-1 on peripheral blood monocytes and its role in mononuclear cell reactivity to autoantigen in rheumatoid arthritis. Rheumatology (Oxford) 53(2), 250-259 (2014).
70. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from infuenza infection. Nat. Med. 14(5), 558-564 (2008).
71. Sasmono RT, Oceandy D, Pollard JW et al. A macrophage colony-stimulating factor receptor-green fuorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. Blood 101(3), 1155-1163 (2003).
72. Sasmono RT, Williams E. Generation and characterization of MacGreen mice, the Cfs1r-EGFP transgenic mice. Methods Mol. Biol. 844, 157-176 (2012).
73. Sasmono RT, Ehrnsperger A, Cronau SL et al. Mouse neutrophilic granulocytes express mRNA encoding the macrophage colony-stimulating factor receptor (CSF-1R) as well as many other macrophage-specifc transcripts and can transdifferentiate into macrophages in vitro in response to CSF-1. J. Leukoc. Biol. 82(1), 111-123 (2007).
74. Schneider C, Nobs SP, Heer AK et al. Alveolar macrophages are rssential for protection from respiratory failure and associated morbidity following infuenza virus infection. PLoS Pathog. 10(4), e1004053 (2014).
75. Purnama C, Ng SL, Tetlak P et al. Transient ablation of alveolar macrophages leads to massive pathology of infuenza infection without affecting cellular adaptive immunity Eur. J. Immunol. 44(7), 2003-2012 (2014).
76. Aggarwal NR, King LS, DAlessio FR. Diverse macrophage populations mediate acute lung infammation and resolution. Am. J. Physiol. Lung Cell. Mol. Physiol. 306(8), L709-L725 (2014).
77. Hussell T, Bell TJ. Alveolar macrophages: plasticity in a tissue-specifc context. Nat. Rev. Immunol. 14(2), 81-93 (2014).
78. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y Avian fu: infuenza virus receptors in the human airway. Nature 440(7083), 435-436 (2006).
79. Couceiro JN, Paulson JC, Baum LG. Infuenza virus strains selectively recognize sialyloligosaccharides on human respiratory epithelium; the role of the host cell in selection of hemagglutinin receptor specifcity. Virus Res. 29(2), 155-165 (1993).
80. Van Riel D, Munster VJ, De Wit E et al. H5N1 virus attachment to lower respiratory tract. Science 312(5772), 399 (2006).
81. Nicholls JM, Peiris JS, Guan Y. Sialic acid and receptor expression on the respiratory tract in normal subjects and H5N1 and non-avian infuenza patients. Hong Kong Med. J. 15(3 Suppl. 4), 16-20 (2009).
82. Nicholls JM, Bourne AJ, Chen H, Guan Y, Peiris JS. Sialic acid receptor detection in the human respiratory tract: evidence for widespread distribution of potential binding sites for human and avian infuenza viruses. Respir. Res. 8, 73 (2007).
83. Ibricevic A, Pekosz A, Walter MJ et al. Infuenza virus receptor specifcity and cell tropism in mouse and human airway epithelial cells. J. Virol. 80(15), 7469-7480 (2006).
84. Shelton H, Ayora-Talavera G, Ren J et al. Receptor binding profles of avian infuenza virus hemagglutinin subtypes on human cells as a predictor of pandemic potential. J. Virol. 85(4), 1875-1880 (2011).
85. Cauldwell AV, Long JS, Moncorge O, Barclay WS. Viral determinants of infuenza A host range. J. Gen. Virol. 95(Pt 6), 1193-1210 (2014).
86. Lakdawala SS, Shih AR, Jayaraman A et al. Receptor specifcity does not affect replication or virulence of the 2009 pandemic H1N1 infuenza virus in mice and ferrets. Virology 446(1-2), 349-356 (2013).
87. Londrigan SL, Tate MD, Brooks AG, Reading PC. Cell-surface receptors on macrophages and dendritic cells for attachment and entry of infuenza virus. J. Leukoc. Biol. 92(1), 97-106 (2012).
88. Reading PC, Miller JL, Anders EM. Involvement of the mannose receptor in infection of macrophages by infuenza virus. J. Virol. 74 (11), 5190-5197 (2000).
89. Upham JP, Pickett D, Irimura T, Anders EM, Reading PC. Macrophage receptors for infuenza A virus: role of the macrophage galactose-type lectin and mannose receptor in viral entry. J. Virol. 84(8), 3730-3737 (2010).
90. Ng WC, Liong S, Tate MD et al. The macrophage galactose-type lectin can function as an attachment and entry receptor for infuenza virus. J. Virol. 88 (3), 1659-1672 (2014).
91. Yu WC, Chan RW, Wang J et al. Viral replication and innate host responses in primary human alveolar epithelial cells and alveolar macrophages infected with infuenza H5N1 and H1N1 viruses. J. Virol. 85(14), 6844-6855 (2011).
92. Tate MD, Brooks AG, Reading PC. Correlation between sialic acid expression and infection of murine macrophages by different strains of infuenza virus. Microbes Infect. 13(2), 202-207 (2011).
93. Tate MD, Schilter HC, Brooks AG, Reading PC. Responses of mouse airway epithelial cells and alveolar macrophages to virulent and avirulent strains of infuenza A virus. Viral Immunol. 24(2), 77-88 (2011).
94. Tate MD, Pickett DL, Van Rooijen N, Brooks AG, Reading PC. Critical role of airway macrophages in modulating disease severity during infuenza virus infection of mice. J. Virol. 84(15), 7569-7580 (2010).
95. Reading PC, Morey LS, Crouch EC, Anders EM. Collectin-mediated antiviral host defense of the lung: evidence from infuenza virus infection of mice. J. Virol. 71(11), 8204-8212 (1997).
96. Reading PC, Whitney PG, Pickett DL, Tate MD, Brooks AG. Infuenza viruses differ in ability to infect macrophages and to induce a local infammatory response following intraperitoneal injection of mice. Immunol. Cell Biol. 88(6), 641-650 (2010).
97. Van Riel D, Leijten LM, Van Der Eerden M et al. Highly pathogenic avian infuenza virus H5N1 infects alveolar macrophages without virus production or excessive TNF-alpha induction. PLoS Pathog. 7(6), e1002099 (2011).
98. Rodgers BC, Mims CA. Role of macrophage activation and interferon in the resistance of alveolar macrophages from infected mice to infuenza virus. Infect. Immun. 36(3), 1154-1159 (1982).
99. Cline TD, Karlsson EA, Seufzer BJ, Schultz-Cherry S. The hemagglutinin protein of highly pathogenic H5N1 infuenza viruses overcomes an early block in the replication cycle to promote productive replication in macrophages. J. Virol. 87(3), 1411-1419 (2013).
100. Perrone LA, Plowden JK, Garcia-Sastre A, Katz JM, Tumpey TM. H5N1 and 1918 pandemic infuenza virus infection results in early and excessive infltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog. 4(8), e1000115 (2008).
101. Weinheime r VK, Becher A, Tonnies M et al. Infuenza A viruses target type II pneumocytes in the human lung. J. Infect. Dis. 206(11), 1685-1694 (2012).
102. Kim HM, Kang YM, Ku KB et al. The severe pathogenicity of alveolar macrophage-depleted ferrets infected with 2009 pandemic H1N1 infuenza virus. Virology 444(1-2), 394-403 (2013).
103. Kim HM, Lee YW, Lee KJ et al. Alveolar macrophages are indispensable for controlling infuenza viruses in lungs of pigs. J. Virol. 82(9), 4265-4274 (2008).
104. Maines TR, Lu XH, Erb SM et al. Avian infuenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J. Virol. 79(18), 11788-11800 (2005).
105. Ogiwara H, Yasui F, Munekata K et al. Histopathological evaluation of the diversity of cells susceptible to H5N1 virulent avian infuenza virus. Am. J. Pathol. 184(1), 171-183 (2014).
106. Manicassamy B, Manicassamy S, Belicha-Villanueva A, Pisanelli G, Pulendran B, Garcia-Sastre A. Analysis of in vivo dynamics of infuenza virus infection in mice using a GFP reporter virus. Proc. Natl Acad. Sci. USA 107(25), 11531-11536 (2010).
107. Hoeve MA, Nash AA, Jackson D, Randall RE, Dransfeld I. Infuenza virus A infection of human monocyte and macrophage subpopulations reveals increased susceptibility associated with cell differentiation. PLoS ONE 7(1), e29443 (2012).
108. Short KR, Brooks AG, Reading PC, Londrigan SL. The fate of infuenza A virus after infection of human macrophages and dendritic cells. J. Gen. Virol. 93(Pt 11), 2315-2325 (2012).
109. Cheung CY, Poon LLM, Lau AS et al. Induction of proinfammatory cytokines in human macrophages by infuenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 360(9348), 1831-1837 (2002).
110. Zhou J, Law HK, Cheung CY, Ng IH, Peiris JS, Lau YL. Differential expression of chemokines and their receptors in adult and neonatal macrophages infected with human or avian infuenza viruses. J. Infect. Dis. 194(1), 61-70 (2006).
111. Herold S, Steinmueller M, Von Wulffen W et al. Lung epithelial apoptosis in infuenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. J. Exp. Med. 205(13), 3065-3077 (2008).
112. Gao R, Bhatnagar J, Blau DM et al. Cytokine and chemokine profles in lung tissues from fatal cases of 2009 pandemic infuenza A (H1N1): role of the host immune response in pathogenesis. Am. J. Pathol. 183 (4), 1258-1268 (2013).
113. Ekchariyawat P, Thitithanyanont A, Sirisinha S, Utaisincharoen P. Apoptosis induced by avian H5N1 virus in human monocyte-derived macrophages involves TRAIL-inducing caspase-10 activation. Innate Immun. 18(3), 390-397 (2012).
114. Metzger DW, Sun K. Immune dysfunction and bacterial coinfections following infuenza. J. Immunol. 191(5), 2047-2052 (2013).
115. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 174(1-2), 83-93 (1994).
116. Diamond MS, Farzan M. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat. Rev. Immunol. 13(1), 46-57 (2013).
117. Desai TM, Marin M, Chin CR, Savidis G, Brass AL, Melikyan GB. IFITM3 restricts infuenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. PLoS Pathog. 10 (4), e1004048 (2014).
118. Everitt AR, Clare S, Pertel T et al. IFITM3 restricts the morbidity and mortality associated with infuenza. Nature 484(7395), 519-523 (2012).
119. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic infuenza: implications for pandemic infuenza preparedness. J. Infect. Dis. 198(7), 962-970 (2008).
120. Smith AM, Adler FR, Ribeiro RM et al. Kinetics of coinfection with infuenza A virus and Streptococcus pneumoniae. PLoS Pathog. 9(3), e1003238 (2013).
121. Snelgrove RJ, Godlee A, Hussell T. Airway immune homeostasis and implications for infuenza-induced infammation. Trends Immunol. 32(7), 328-334 (2011).
122. Holt PG, Strickland DH, Wikstrom ME, Jahnsen FL. Regulation of immunological homeostasis in the respiratory tract. Nat. Rev. Immunol. 8(2), 142-152 (2008).
123. Kash JC, Walters KA, Davis AS et al. Lethal synergism of 2009 pandemic H1N1 infuenza virus and Streptococcus pneumoniae coinfection is associated with loss of murine lung repair responses. MBio 2(5), e00172-11 (2011).
124. Alymova I V, Portner A, Takimoto T, Boyd KL, Babu YS, McCullers JA. The novel parainfuenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae. Antimicrob. Agents. Chemother. 49(1), 398-405 (2005).
125. McCullers JA. The co-pathogenesis of infuenza viruses with bacteria in the lung. Nat. Rev. Microbiol. 12(4), 252-262 (2014).
126. Ghosh S, Gregory D, Smith A, Kobzik L. MARCO regulates early infammatory responses against infuenza: a useful macrophage function with adverse outcome. Am. J. Respir. Cell Mol. Biol. 45 (5), 1036-1044 (2011).
127. Didierlaurent A, Goulding J, Patel S et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory infuenza infection. J. Exp. Med. 205(2), 323-329 (2008).
128. Goulding J, Godlee A, Vekaria S, Hilty M, Snelgrove R, Hussell T. Lowering the threshold of lung innate immune cell activation alters susceptibility to secondary bacterial superinfection. J. Infect. Dis. 204(7), 1086-1094 (2011).
129. Shahangian A, Chow EK, Tian X et al. Type I IFNs mediate development of postinfuenza bacterial pneumonia in mice. J. Clin. Invest. 119 (7), 1910-1920 (2009).
130. Mcnamee LA, Harmsen AG. Both infuenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a secondary Streptococcus pneumoniae infection. Infect. Immun. 74(12), 6707-6721 (2006).
131. Naessens T, Vander Beken S, Bogaert P et al. Innate imprinting of murine resident alveolar macrophages by allergic bronchial infammation causes a switch from hypo-infammatory to hyperinfammatory reactivity. Am. J. Pathol. 181(1), 174-184 (2012).
132. Price GE, Gaszewska-Mastarlarz A, Moskophidis D. The role of alpha/beta and gamma interferons in development of immunity to infuenza A virus in mice. J. Virol. 74(9), 3996-4003 (2000).
133. Breslow-Deckman JM, Mattingly CM, Birket SE et al. Linezolid decreases susceptibility to secondary bacterial pneumonia postinfuenza infection in mice through its effects on IFN-gamma. J. Immunol. 191(4), 1792-1799 (2013).
134. Van Der Sluijs KF, Van Elden LJ, Nijhuis M et al. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after infuenza infection. J. Immunol. 172(12), 7603-7609 (2004).
135. Van Der Sluijs KF, Nijhuis M, Levels JH et al. Infuenza-induced expression of indoleamine 2, 3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia. J. Infect. Dis. 193(2), 214-222 (2006).
136. Sun K, Torres L, Metzger DW. A detrimental effect of interleukin-10 on protective pulmonary humoral immunity during primary infuenza A virus infection. J. Virol. 84(10), 5007-5014 (2010).
137. McKinstry KK, Strutt TM, Buck A et al. IL-10 defciency unleashes an infuenza-specifc Th17 response and enhances survival against high-dose challenge. J. Immunol. 182(12), 7353-7363 (2009).
138. Chen WH, Toapanta FR, Shirey KA et al. Potential role for alternatively activated macrophages in the secondary bacterial infection during recovery from infuenza. Immunol. Lett. 141(2), 227-234 (2012).
139. Alber A, Howie SE, Wallace WA, Hirani N. The role of macrophages in healing the wounded lung. Int. J. Exp. Pathol. 93(4), 243-251 (2012).
140. Habibzay M, Weiss G, Hussell T. Bacterial superinfection following lung infammatory disorders. Future Microbiol. 8(2), 247-256 (2013).
141. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 379(9823), 1341-1351 (2012).
142. Walzl G, Tafuro S, Moss P, Openshaw PJ, Hussell T. Infuenza virus lung infection protects from respiratory syncytial virus-induced immunopathology. J. Exp. Med. 192(9), 1317-1326 (2000).
143. Barton ES, White DW, Cathelyn JS et al. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 447(7142), 326-329 (2007).
144. Saito F, Ito T, Connett JM et al. MHV68 latency modulates the host immune response to infuenza A virus. Infammation 36(6), 1295-1303 (2013).
145. Nicol MQ, Mathys JM, Pereira A, Ollington K, Ieong MH, Skolnik PR. Human immunodefciency virus infection alters tumor necrosis factor alpha production via Toll-like receptor-dependent pathways in alveolar macrophages and U1 cells. J. Virol. 82(16), 7790-7798 (2008).
146. Tachado SD, Li X, Bole M et al. MyD88-dependent TLR4 signaling is selectively impaired in alveolar macrophages from asymptomatic HIV+ persons. Blood 115 (17), 3606-3615 (2010).